Meeting on the Mesa 2021 | Advantages of allogeneic NK cell therapy

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, discusses the benefits of developing allogeneic natural killer (NK) cell therapies. Allogeneic therapies have gained traction in recent years within the advanced therapies sector, due to lower manufacturing costs. NK cell therapies additionally lack T-cell receptors unlike chimeric antigen receptor (CAR) T-cell products, mitigating the risk of graft-versus-host disease (GvHD), and have a better safety profile due to minimal cytokine release syndrome. This interview took place at Meeting on the Mesa 2021.